Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as a solution for injection for intravenous use. It treats certain adult cancers, notably non‑small cell lung cancer and breast cancer, by interfering with cell division.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Navirel (vinorelbine) is employed in oncology for malignancies that rely on rapid cell division. - Non‑small cell lung cancer: improves disease control and overall survival in advanced stages. - Breast cancer (adjuvant setting): used as part of combination regimens to reduce recurrence risk. - Metastatic breast cancer: provides palliation and tumor burden reduction when combined with other agents.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional, may require anti‑emetic support. - Neutropenia: reduced white blood cell count, increasing infection risk. - Alopecia: hair loss that is usually reversible. - Fatigue: generalized tiredness during treatment cycles. - Constipation: bowel motility changes requiring dietary management.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection: requires immediate medical attention. - Pulmonary toxicity: dyspnoea or interstitial pneumonitis. - Peripheral neuropathy: tingling or numbness of extremities. - Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity. - Cardiac arrhythmia: irregular heart rhythms observed in susceptible patients.

Before initiating Navirel, clinicians should assess patient suitability and monitor for potential complications. - Blood count monitoring: perform complete blood counts before each cycle to detect neutropenia. - Liver function assessment: evaluate hepatic enzymes as vinorelbine is metabolised hepatically. - Neuropathy evaluation: avoid in patients with pre‑existing peripheral neuropathy. - Cardiac risk review: use cautiously in patients with known cardiac disease or arrhythmias. - Concomitant myelosuppressants: avoid or adjust doses when combined with other bone‑marrow suppressing agents. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with several drug classes, influencing efficacy or toxicity.

Major Interactions (Avoid): - Concurrent vinca alkaloids: additive myelosuppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase vinorelbine exposure. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - Anticoagulants (warfarin, DOACs): enhanced bleeding risk. - Diuretics: potential for electrolyte disturbances when combined with vinorelbine‑induced nausea.